Cannabis May Treat Lou Gehrig’s Disease
New research shows marijuana-based treatments could delay the progression of a fatal condition known as Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS).
Topic
GW Pharmaceuticals
17 articles
Marijuana-Epilepsy Drug Cuts Seizures in Half
British drug maker GW Pharmaceuticals released the first results on the efficacy and safety of Epidiolex, with an average reduction in seizure frequency of 50% among a group of 27 children and young adults with treatment-resistant epilepsy.
Georgia Partners With GW Pharmaceuticals on CBD Study
The state of Georgia has entered an agreement with GW Pharmaceuticals and Georgia Regents University to trial a marijuana-based epilepsy treatment.
Cannabis FactsLink
Drug Made From Cannabis Could Treat Schizophrenia
A drug from the marijuana compound cannabidiol (CBD) entered human trials to treat schizophrenia. GW Pharmaceuticals announced Phase 2 clinical trials.
Medical Marijuana Update (2014.03.12)
Here's the latest major medical marijuana news around the United States from the past week, as of March 12, 2014.
Law & PoliticsLink
France’s Ministry of Health Approves Cannabis-Based Sativex Medicine
France’s ministry of health announced Thursday that it has approved Sativex, a cannabis-based mouth spray produced by GW pharmaceutricals. Sativex will be available in
Families Continue to Come to Colorado for Cannabis Treatment
As knowledge of cannabis as treatment for children becomes more accepted, families from less weed-friendly places come to Colorado for cannabis treatment.
Marijuana NewsLink
FDA Approves Plant-Derived CBD to Treat Children
GW Pharmaceuticals announced the FDA approval of one of its drugs that's basically just concentrated, plant-derived CBD.
Irish Doctors Will Be Allowed to Prescribe Sativex
Irish Minister of State Alex White said he plans to “amend the regulations to allow a newly authorised medicinal product containing cannabis extract to be prescribed, supplied and used by patients.
Long-Ignored Cannabinoid THCV May Hold Key to Diabetes
A recent discovery is that THCV, which is structurally similar to THC, holds great promise in treating metabolic syndrome and possibly diabetes as well.
GW Pharmaceuticals, Legal Marijuana Monopoly, Launches Sativex Spray in Italy
GW Pharmaceuticals has launched their Sativex cannabis extract spray in Italy for use by Multiple Sclerosis (MS) patients.
CannabusinessLink
The Original Marijuana Stock Files for US IPO
GWP, the maker of Sativex and undeniably the original marijuana stock files for U.S. IPO
Best of the WebLink
Encouraging Anti-diabetic Results for New Cannabinoid Drug from GW Pharmaceuticals
A new cannabis-based medicine from GW Pharmaceuticals (GWP42004) has been identified as a potential drugtreatment for patients with type 2 diabetes.
Little-Known Cannabinoid May Treat Epileptic Seizures
There is "big, historical, anecdotal evidence" that cannabinoids can be used to control human epileptic seizures.
Marijuana NewsLink
Cannabis Anti-Convulsant Shakes Up Epilepsy Treatment
Ben Whalley at the University of Reading, UK , and colleagues worked with GW Pharmaceuticals in Wiltshire, UK, to investigate the anti-convulsant properties of cannabidivarin (CBDV) , a little-studied chemical found in…
Marijuana NewsLink
THCV and Cannabidiol in Cannabis May Fight Obesity
GW Pharmaceuticals believes two compounds in cannabis, THCV and Cannabidiol may help fight obesity-related diseases. Read more at UPI .